← Leaderboards
Eddie A James
University Of Colorado Denver
$1,014,201
Attributed
$2,028,402
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $522.6K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,028,402 · 1
By mechanism
R01$2,028,402 · 1
Top collaborators
- Kathryn Haskins4 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Roberta Pelanda$15,844,961
- Kathryn Haskins$12,584,495
- Marian J. Rewers$53,889,410
- Peter A Gottlieb$9,273,760
- Aaron W Michels$8,254,447
Others in their field
Other Emerging Leaders on “Agonist”
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Aaron Esser-Kahn · University Of Chicago$13,378,548
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Xinhua Li · Nano Terra, Inc.$11,941,250
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
Research focus
AgonistFundingAutoantigensAntigensAreaAutoreactive T CellAutoreactivityAwardAutoimmune DiabetesBeta CellAutoimmune ResponsesCategoriesCd4 Positive T LymphocytesClone CellsCollaborationsCombinatorialCoupledC-PeptideC-TerminalCytoplasmic GranulesDiabetes MellitusDiabeticDiabetogenicGenerations
Grant awards (4)
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T Cells$488,370
R01 · FY2024 · DK
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T Cells$508,719
R01 · FY2023 · DK
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T Cells$508,719
R01 · FY2022 · DK
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T Cells$522,594
R01 · FY2021 · DK